GU Cancers Symposium 2014 - Results from #60

GU Cancers Symposium 2014 - The initial report of RTOG 0524: Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery... February 3, 2014

GU Cancers Symposium 2014 - Evaluation of outcomes following centralization of cystectomy services in the United Kingdom - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Biology of bladder cancer metastases - Session Highlights February 1, 2014

GU Cancers Symposium 2014 - Somatic genomic alterations in urothelial cancer: Results of the Cancer Genome Atlas (TCGA) bladder cancer analysis - Session Highlights February 1, 2014

GU Cancers Symposium 2014 - The Cancer Genome Atlas (TCGA) bladder cancer update - Session Highlights February 1, 2014

GU Cancers Symposium 2014 - Next generation sequencing technologies: Advancing therapy for urothelial carcinoma - Session Highlights February 1, 2014

GU Cancers Symposium 2014 - Preclinical models for bladder cancer - Session Highlights February 1, 2014

GU Cancers Symposium 2014 - Keynote Lecture: Evolution of prostate cancer genomes - Session Highlights February 1, 2014

GU Cancers Symposium 2014 - Multimodal management of urothelial carcinoma - Session Highlights February 1, 2014

GU Cancers Symposium 2014 - A pooled analysis of RTOG 9906 and 0233 - Session Highlights February 1, 2014

GU Cancers Symposium 2014 - Update on European Organisation for Research and Treatment of Cancer (EORTC) guidelines for bladder cancer - Session Highlights February 1, 2014

GU Cancers Symposium 2014 - Practical use of molecular markers in the management of bladder cancer - Session Highlights February 1, 2014

GU Cancers Symposium 2014 - Best of journals - urologic oncology - Session Highlights February 1, 2014

GU Cancers Symposium 2014 - Best of journals - radiation oncology - Session Highlights January 31, 2014

GU Cancers Symposium 2014 - Best of journals - medical oncology - Session Highlights January 31, 2014

GU Cancers Symposium 2014 - Population pharmacokinetic analysis of abiraterone acetate in healthy volunteers and chemotherapy-naive and chemotherapy-pretreated metastatic castration-resistant prostate cancer patients - Poster January 31, 2014

GU Cancers Symposium 2014 - Response to androgen signaling-directed therapy after treatment with abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer: Post hoc analysis of study COU-AA-302 - Poster January 31, 2014

GU Cancers Symposium 2014 - Does Gleason score predict efficacy of abiraterone acetate (AA) therapy in patients with metastatic castration-resistant prostate cancer? An analysis of AA phase 3 trials - Poster January 31, 2014

GU Cancers Symposium 2014 - Effect of prior abiraterone or enzalutamide on sipuleucel-T manufacture in PROCEED patients - Poster January 31, 2014

GU Cancers Symposium 2014 - Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥ 80 years-old: Data from PROCEED - Poster January 31, 2014

Page 4 of 6